间充质干细胞治疗剖宫产皮肤瘢痕:随机对照试验研究方案
BACKGROUND: Cesarean delivery has already become a very common method of delivery around the world, especially in low-income countries. Hypertrophic scars and wound infections have affected younger mothers and frustrated obstetricians for a long time.…
要点
- MSCs用于剖宫产皮肤瘢痕治疗的安全性和有效性尚待验证。
- 试验采用随机双盲安慰剂对照三臂设计,主要终点为6个月温哥华瘢痕量表评分。
- 低剂量与高剂量组分别使用3×10^6和6×10^6个MSCs,每日一次连续6天。
核心结论
- 该试验旨在评估间充质干细胞治疗剖宫产皮肤瘢痕的安全性和有效性。
研究设计与样本
- 研究时长6个月,包括1周导入期和24周随访。
关键数值与推荐
- 低剂量组使用透皮水凝胶MSCs 3×10^6细胞,高剂量组使用6×10^6细胞,每日一次连续6天。
- 主要终点为第6个月时三组间温哥华瘢痕量表评分的差异。
- 不良事件将记录于病例报告表中。
临床怎么用
- 若试验证实有效,可为剖宫产皮肤瘢痕提供基于MSCs的治疗策略。
局限性
- 单中心设计可能限制结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cesarean delivery has already become a very common method of delivery around the world, especially in low-income countries. Hypertrophic scars and wound infections have affected younger mothers and frustrated obstetricians for a long time. Mesenchymal stem cells (MSCs) have strong potential for self-renewal and differentiation to multilineage cells. Previous studies have demonstrated that MSCs are involved in enhancing diabetic wound healing. Therefore, this study is designed to investigate the safety and efficacy of using MSCs in the treatment of Cesarean section skin scars. METHODS: This trial is a prospective, randomized, double-blind, placebo-controlled, single-center trial with three parallel groups. Ninety eligible participants will be randomly allocated to placebo, low-dose (transdermal hydrogel MSCs; 3 × 106 cells) or high-dose (transdermal hydrogel MSCs; 6 × 106 cells) groups at a 1:1:1 allocation ratio according to a randomization list, once a day for six consecutive days. Study duration will last for 6 months, comprising a 1 week run-in period and 24 weeks of follow-up. The primary aim of this trial is to compare the difference in Vancouver Scar Scale rating among the three groups at the 6th month. Adverse events, including severe and slight signs or symptoms, will be documented in case report forms. The study will be conducted at the Department of Obstetric of Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan. DISCUSSION: This trial is the first investigation of the potential for therapeutic use of MSCs for the management of women's skin scar after Cesarean delivery. The results will give us an effective therapeutic strategy to combat Cesarean section skin scars, even with uterine scarring. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02772289 . Registered on 10 May 2016.
引用
- Fan D, Xia Q, Wu S, et al. Mesenchymal stem cells in the treatment of Cesarean section skin scars: study protocol for a randomized, controlled trial. Trials. 2018. PMID: 29499740. doi:10.1186/s13063-018-2478-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。